The Biomedical Translation Bridge program, delivered by MTPConnect is a $22.3 million Medical Research Future Fund initiative, that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.
The BTB program aims to:
- De-risk and develop ventures so that they can attract further funding opportunities
- Nurture and mentor the next generation of health and medical research innovators in Australia
- Develop ventures to become attractive to the Biomedical Translation Fund (BTF)
- Assist in the development of ventures that aim to ultimately result in preventative interventions, cures and
- Treatments for diseases that address health problems of national significance.
The BTB program is delivered through mentoring and commercialisation advice provided by BTB partner BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.
There are currently 21 projects funded by the BTB program. Round 1, announced in December 2019, saw eight projects selected following a highly competitive application process. Round 2 opened in February 2020 and in mid-May 2020, Round 3 was opened, specifically targeted at COVID-19-related research with the need for rapid deployment. On 3 September 2020, funding was announced for 13 early-stage biomedical projects, including COVID-19 research, for rounds 2 and 3 of the BTB program.
To view the BTB funded projects from Rounds 1, 2 & 3, expand the right menu.
For more information, contact Director of BTB Danielle Shand.
BioCurate is a bold, collaborative venture, dedicated to delivering benefits to the community by helping to advance Australian research and innovation globally. Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate was specifically created to invest in, manage and commercialise innovative Australian medical research. We provide a critical bridge between academia and industry by identifying promising research and accelerating its development for real-world clinical impact, while ensuring scientific and commercial rigour. Our multi-disciplinary team has an extensive global network and a proven track record in producing commercially successful therapies, positioning BioCurate well to drive the most feasible commercial pathway forward and improve people’s lives.”
Visit Biocurate for more information.
UniQuest is a leading university-based commercialisation company, managing the intellectual property (IP) of The University of Queensland (UQ). UniQuest has facilitated more than 100 start-up companies built on UQ IP, a milestone unsurpassed by any other Australian university. These companies have gone on to raise more than $776M to take UQ technologies to market. The Queensland Emory Drug Discovery Initiative (QEDDI), a division of UniQuest, is a small molecule drug discovery and development facility translating The University of Queensland and collaborator’s biomedical research into new medicines to deliver faster health benefits. UniQuest is a partner on the MRFF Targeted Translation Research Accelerator (TTRA) Program with MTPConnect.
Visit UniQuest for more information.
Medical Device Partnering Program (MDPP)
The Medical Device Partnering Program, led by Flinders University, runs an ideas incubator driving entrepreneurial culture within the medtech sector. The Program fosters collaborations between researchers, industry, end-users and government and develops novel medical devices with global market potential. It forms the essential links between clinical need and knowledge with technical expertise and industry know-how. MDPP is also a partner on the MRFF Targeted Translation Research Accelerator (TTRA) Program and the Researcher Exchange and Development within Industry (REDI) initiative with MTPConnect.
Visit MDPP for more information.
Bridge and BridgeTech programs (Queensland University of Technology)
The Bridge Program provides commercialisation training focused on the development of new pharmaceuticals in collaboration with a number of partners including universities and leading pharmaceutical companies. Similarly, the BridgeTech Program provides commercialisation training for researchers and entrepreneurs with a focus on the medtech sector in partnership with Australian universities, medtech companies and industry partners. The BridgeTech and Bridge Program, now in their fourth and fifth year respectively, select up to 100 participants annually from around Australia to take part in these fully-supported training programs. The Bridge and BridgeTech Program is also a partner on the MRFF Researcher Exchange and Development within Industry (REDI) initiative with MTPConnect.
Visit the Bridge Program to learn more about pharmaceutical commercialisation.
Visit the BridgeTech Program for more information about medtech commercialisation.
- Listen to our podcast with Starpharma's Dr Jackie Fairley (published 5 March 2021)
- Listen to our podcast with Vaxine's Professor Nikolai Petrovsky (published 13 August 2020)
- Listen to our podcast for a live R2 Information Session at the Melbourne Convention and Exhibition Centre (published 7 February 2020)
- Listen to our podcast with Noisy Gut's Dr Josephine Muir (published 19 September 2019)
- Listen to our podcast for a live R1 Information Session at the Victorian Comprehensive Cancer Centre (VCCC) in Melbourne (published 14 June 2019).